Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...
The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista.
The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...
President-elect Donald Trump on Friday named Johns Hopkins University surgeon Marty Makary to lead the Food and Drug ...
In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...
Venture capital firms incubate, grow and finance dozens of drug companies each year. Follow the money they channel into the ...
Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...
The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a ...
Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its ...
Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck ...
Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback